药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Tiludronic acid
Duligotuzumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Duligotuzumab.
Tiludronic acid
Gevokizumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Gevokizumab.
Tiludronic acid
Sotatercept
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Sotatercept.
Tiludronic acid
Tarextumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Tarextumab.
Tiludronic acid
Fulranumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Fulranumab.
Tiludronic acid
Patritumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Patritumab.
Tiludronic acid
Lorvotuzumab mertansine
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Lorvotuzumab mertansine.
Tiludronic acid
Urelumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Urelumab.
Tiludronic acid
Visilizumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Visilizumab.
Tiludronic acid
Gantenerumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Gantenerumab.
Tiludronic acid
Benralizumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Benralizumab.
Tiludronic acid
Ocrelizumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Ocrelizumab.
Tiludronic acid
Anifrolumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Anifrolumab.
Tiludronic acid
Rilotumumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Rilotumumab.
Tiludronic acid
Crenezumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Crenezumab.
Tiludronic acid
Avelumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Avelumab.
Tiludronic acid
Varlilumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Varlilumab.
Tiludronic acid
Lebrikizumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Lebrikizumab.
Tiludronic acid
Vadastuximab Talirine
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Vadastuximab Talirine.
Tiludronic acid
Romosozumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Romosozumab.